From perspectives to decisions.
A lightweight example of how responses can focus the next workshop.
Synthetic sample data. These three fictional responses demonstrate the summary. They are not Sun Pharma findings or recommended mappings.
Evidence connections
Number of respondents associating each deliverable with a critical question. Denominator: 3 responses in this view.
| Critical question | D1 | D2 | D3 | D4 | D5 |
|---|---|---|---|---|---|
| Q1 · Patient population | 3 / 3 | 0 / 3 | 0 / 3 | 0 / 3 | 1 / 3 |
| Q2 · Priority segments | 3 / 3 | 3 / 3 | 0 / 3 | 0 / 3 | 0 / 3 |
| Q3 · Competitive context | 0 / 3 | 0 / 3 | 3 / 3 | 3 / 3 | 1 / 3 |
| Q4 · Assumptions & uncertainty | 3 / 3 | 0 / 3 | 3 / 3 | 3 / 3 | 3 / 3 |
D1: Patient population & market sizing · D2: Market segmentation · D3: Competitive landscape · D4: Product profile & differentiation · D5: Market access landscape
Ownership perspectives
Functions reporting a lead/accountable role. Multiple claims are prompts for discussion.
- D1 · Patient population & market sizing: MI&A
- D2 · Market segmentation: MI&A
- D3 · Competitive landscape: MI&A
- D4 · Product profile & differentiation: Clinical Development
- D5 · Market access landscape: Market Access
Open questions for the workshop
Missing · MI&A · Q4: Scenario-based opportunity sensitivity model. Make upside/downside scenarios and their assumptions explicit.
Conditional · Market Access · D5: Depth should reflect payer restrictions and reimbursement complexity for the launch.
Dependency · Clinical Development: Clinical label assumptions must be agreed before the addressable population is finalized.
Read every connection in the context of function and expertise. A low selection count does not make a deliverable unnecessary. These counts identify questions to explore; they do not establish consensus or approved ownership.